| Today’s Big NewsJan 17, 2024 |
| By Annalee Armstrong,Gabrielle Masson Biotech executives are reaching into their bag of tricks and coming up with wild ways to access capital. It's not enough to have M&A in mind or plan for an IPO. You need to have both underway, just in case. |
|
|
|
By Nick Paul Taylor Roche has bagged a phase 3 win in TIGIT. But the victory falls short of being a clear-cut endorsement of the mechanism, with the use of a comparator that is no longer the standard of care complicating efforts to tease out the impact of the investigational antibody. |
By Annalee Armstrong As green shoots slowly push from the scorched Earth biotech markets, ReCode Therapeutics CEO Shehnaaz Suliman, M.D., is watching closely, biding her time for a potential second half IPO. |
By James Waldron Kyverna Therapeutics has become the latest example of a growing new year trend for biotech IPOs, with the company hoping that going public will help fund its two lead CD19 CAR-T therapies through the clinic. |
|
This whitepaper reveals how to strategically scale processes, offering developers flexibility from 1,000L to an industry-leading 5,000L in a single-use bioreactor. Meticulous optimization ensures high-quality drug products, while expert-led parameter fine-tuning guarantees consistent growth across scales. Explore how suspension cells lead the way, providing a robust and adaptable manufacturing platform for gene therapy breakthroughs. .png)
|
|
By James Waldron Despite losing a couple of Big Pharma collaborators, Dewpoint Therapeutics is gearing up to finally take its lead biologic condensates into the clinic, clearing out 18 unwanted roles and narrowing its pipeline to make space for the right candidates. |
By Nick Paul Taylor Regenxbio and AbbVie have taken a small step toward in-office administration of their eye disease gene therapy candidate. Interim phase 2 data suggest the prospect can be given safely at the doctor’s office, opening up a convenient delivery option for the wet age-related macular degeneration (AMD) treatment. |
By Max Bayer Windtree is handing over Greater China and Asia Pacific rights to Lee's Pharma for three out of four pipeline assets. Lee's had already nabbed global rights to Windtree's fourth asset. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Max Bayer Gilead is calling off an expansion of its Oceanside biologics site and plans to move "the majority" of the team to Foster City. A Gilead spokesperson said Kite's viral vector manufacturing facility is not affected by the move. |
By Kevin Dunleavy Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval came more than two months ahead of the FDA's March 30 decision date. |
By Joseph Keenan U.K. biotech Compass Pathways inked a research collaboration deal with New Jersey’s Hackensack Meridian Health regarding the delivery model design of its investigational COMP360 psilocybin treatment. |
By Nick Paul Taylor Novo Nordisk is ramping up promotion of its weight-loss drug Wegovy. Having paused some promotions as demand swamped supply last year, the Danish drugmaker has now started running a TV spot to show the impact losing weight can have on people’s lives. |
By Andrea Park For the third time since 2022, when it purchased infusion pump maker Ivenix for $240 million, Fresenius Kabi has earned a Class I rating from the FDA for a recall of the Ivenix medication delivery technology. |
By Anastassia Gliadkovskaya The focus on looming climate threats continues, with the World Economic Forum kicking off this week with a report on the topic. The analysis focused on how climate will likely transform the healthcare landscape over the next two decades, as well as actionable strategies to mitigate and prepare for the looming threat. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
